Literature DB >> 24045940

Binding of the sialic acid-binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of β-catenin and subsequent cell growth.

Shuhei Tanida1, Kaoru Akita, Akiko Ishida, Yugo Mori, Munetoyo Toda, Mizue Inoue, Mariko Ohta, Masakazu Yashiro, Tetsuji Sawada, Kosei Hirakawa, Hiroshi Nakada.   

Abstract

Because MUC1 carries a variety of sialoglycans that are possibly recognized by the siglec family, we examined MUC1-binding siglecs and found that Siglec-9 prominently bound to MUC1. An immunochemical study showed that Siglec-9-positive immune cells were associated with MUC1-positive cells in human colon, pancreas, and breast tumor tissues. We investigated whether or not this interaction has any functional implications for MUC1-expressing cells. When mouse 3T3 fibroblast cells and a human colon cancer cell line, HCT116, stably transfected with MUC1cDNA were ligated with recombinant soluble Siglec-9, β-catenin was recruited to the MUC1 C-terminal domain, which was enhanced on stimulation with soluble Siglec-9 in dose- and time-dependent manners. A co-culture model of MUC1-expressing cells and Siglec-9-expressing cells mimicking the interaction between MUC1-expressing malignant cells, and Siglec-9-expressing immune cells in a tumor microenvironment was designed. Brief co-incubation of Siglec-9-expressing HEK293 cells, but not mock HEK293 cells, with MUC1-expressing cells similarly enhanced the recruitment of β-catenin to the MUC1 C-terminal domain. In addition, treatment of MUC1-expressing cells with neuraminidase almost completely abolished the effect of Siglec-9 on MUC1-mediated signaling. The recruited β-catenin was thereafter transported to the nucleus, leading to cell growth. These findings suggest that Siglec-9 expressed on immune cells may play a role as a potential counterreceptor for MUC1 and that this signaling may be another MUC1-mediated pathway and function in parallel with a growth factor-dependent pathway.

Entities:  

Keywords:  Lectin; Mucins; Signaling; Tumor Microenvironment; β-Catenin

Mesh:

Substances:

Year:  2013        PMID: 24045940      PMCID: PMC3814777          DOI: 10.1074/jbc.M113.471318

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

Review 1.  Siglecs in the immune system.

Authors:  P R Crocker; A Varki
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

2.  Identification of MUC1 proteolytic cleavage sites in vivo.

Authors:  S Parry; H S Silverman; K McDermott; A Willis; M A Hollingsworth; A Harris
Journal:  Biochem Biophys Res Commun       Date:  2001-05-11       Impact factor: 3.575

3.  Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland.

Authors:  J A Schroeder; M C Thompson; M M Gardner; S J Gendler
Journal:  J Biol Chem       Date:  2001-01-22       Impact factor: 5.157

4.  Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells.

Authors:  Kevin Lock; Jiquan Zhang; Jinhua Lu; Szu Hee Lee; Paul R Crocker
Journal:  Immunobiology       Date:  2004       Impact factor: 3.144

5.  The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin.

Authors:  Y Li; H Kuwahara; J Ren; G Wen; D Kufe
Journal:  J Biol Chem       Date:  2001-01-10       Impact factor: 5.157

6.  Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin.

Authors:  D Nath; A Hartnell; L Happerfield; D W Miles; J Burchell; J Taylor-Papadimitriou; P R Crocker
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

7.  Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways.

Authors:  T Angata; A Varki
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

8.  The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin.

Authors:  Y Li; J Ren; W Yu; Q Li; H Kuwahara; L Yin; K L Carraway; D Kufe
Journal:  J Biol Chem       Date:  2001-08-01       Impact factor: 5.157

9.  Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism.

Authors:  Chunming Liu; Yiming Li; Mikhail Semenov; Chun Han; Gyeong Hun Baeg; Yi Tan; Zhuohua Zhang; Xinhua Lin; Xi He
Journal:  Cell       Date:  2002-03-22       Impact factor: 41.582

Review 10.  MUC1, the renaissance molecule.

Authors:  S J Gendler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.698

View more
  36 in total

Review 1.  Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression.

Authors:  Robert P Schleimer; Ronald L Schnaar; Bruce S Bochner
Journal:  Curr Opin Allergy Clin Immunol       Date:  2016-02

Review 2.  Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.

Authors:  Seema Chugh; Vinayaga S Gnanapragassam; Maneesh Jain; Satyanarayana Rachagani; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2015-08-28

3.  GABA selectively increases mucin-1 expression in isolated pig jejunum.

Authors:  Jörg R Aschenbach; Carolin Deiner; Hannah-Sophie Braun; Gerhard Sponder; Robert Pieper
Journal:  Genes Nutr       Date:  2015-10-15       Impact factor: 5.523

Review 4.  MUC1: a novel metabolic master regulator.

Authors:  Kamiya Mehla; Pankaj K Singh
Journal:  Biochim Biophys Acta       Date:  2014-01-11

Review 5.  Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.

Authors:  Takashi Angata; Corwin M Nycholat; Matthew S Macauley
Journal:  Trends Pharmacol Sci       Date:  2015-10       Impact factor: 14.819

6.  MUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-κB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells.

Authors:  Yugo Mori; Kaoru Akita; Shuhei Tanida; Akiko Ishida; Munetoyo Toda; Mizue Inoue; Masakazu Yashiro; Tetsuji Sawada; Kosei Hirakawa; Hiroshi Nakada
Journal:  J Biol Chem       Date:  2014-11-04       Impact factor: 5.157

Review 7.  Viewing Siglecs through the lens of tumor immunology.

Authors:  Isabella Fraschilla; Shiv Pillai
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

8.  Endogenous airway mucins carry glycans that bind Siglec-F and induce eosinophil apoptosis.

Authors:  Takumi Kiwamoto; Toshihiko Katoh; Michael Tiemeyer; Bruce S Bochner; Christopher M Evans; William J Janssen; Mary E Brummet; Sherry A Hudson; Zhou Zhu
Journal:  J Allergy Clin Immunol       Date:  2014-12-12       Impact factor: 10.793

Review 9.  Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.

Authors:  Kayluz Frias Boligan; Circe Mesa; Luis Enrique Fernandez; Stephan von Gunten
Journal:  Cell Mol Life Sci       Date:  2014-12-07       Impact factor: 9.261

10.  Binding of Galectin-3, a β-Galactoside-binding Lectin, to MUC1 Protein Enhances Phosphorylation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) and Akt, Promoting Tumor Cell Malignancy.

Authors:  Yugo Mori; Kaoru Akita; Masakazu Yashiro; Tetsuji Sawada; Kosei Hirakawa; Takeomi Murata; Hiroshi Nakada
Journal:  J Biol Chem       Date:  2015-09-04       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.